Compare Moderna, Inc. (MRNA) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Packaging Corporation of America — how do they compare? Moderna, Inc. trades at $136.4 (market cap $56.02B), while Packaging Corporation of America trades at $227.95 (market cap $20.67B). The key difference: Moderna, Inc. is far larger — about 2.7× Packaging Corporation of America's market cap, and Packaging Corporation of America pays a 2.59% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PKG | |
|---|---|---|
Market Cap | $56.02B | $20.67B |
Sector | Health | Technology |
52-Week High | $174.38 | $257.43 |
52-Week Low | $22.36 | $191.68 |
Enterprise Value | $52.17B | $24.48B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Packaging Corporation of America (PKG) trades at $231.99, down 2.22% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 30.13 above industry averages, while profitability metrics indicate solid ROE of 14.79% amid margin pressures. Recent news highlights dividend declarations and CEO participation in industry conferences, though cash flow trends show negative net flows driven by significant capital investments.
PKG presents a cautious outlook with analyst consensus leaning hold (57.69%) despite a $272.83 price target suggesting 17.6% upside. Investment appeal hinges on execution amid cost headwinds, while risks include margin compression and competitive pressures. The technical setup near support at $230 requires monitoring for potential breakdown or reversal signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
